Ketamine beat midazolam in treatment-resistant bipolar depression
In the Ket-BD trial, four IV ketamine infusions over two weeks lowered depression scores more than an active placebo, with no manic switches observed in 63 analysed patients.
Six months after a repeat ketamine course, only 17% still counted as responders
The KADS extension followed 130 patients who had already been through a ketamine trial. Response fell from 30% at treatment's end to 17% a month later.
One ketamine infusion cut suicidal symptoms within a day, a 26-trial pooling finds
The meta-analysis behind ketamine's widening off-label use for suicidal crisis quantifies what 1,166 patients across two decades of trials actually showed — and where the evidence runs out.
At-home ketamine's entire evidence base came from the companies selling it
A systematic review screened 3,857 records and found three eligible studies, every one produced by a US commercial provider and every one at critical risk of bias.